Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.

ABSTRACT:

Background

The search for biomarkers to evaluate ovarian cancer (OC) homologous recombination (HR) function and predict the response to therapy is an urgent clinical need to improve the selection of patients who could benefit from platinum- and olaparib (poly-ADP ribose polymerase inhibitors, PARPi)-based therapies.

Methods

We used a large collection of OC patient-derived xenografts (PDXs) (n = 47) and evaluated their HR status based on BRCA1/2 mutations, BRCA1 promoter methylation and the HRDetect score. RAD51 foci were quantified in formalin-fixed, paraffin-embedded untreated tumour specimens by immunofluorescence and the messenger RNA expression of 21 DNA repair genes by real-time PCR.

Results

Tumour HR deficiency predicted both platinum and olaparib responses. The

SUBMITTER: Guffanti F 

PROVIDER: S-EPMC8727677 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature